Antiretroviral News and Research

RSS

New study explores the effect of food insecurity on treating HIV-infected pregnant women in Uganda

In Uganda the prescription of three antiretroviral (ARV) drugs, which aim to suppress the virus to prevent disease progression, have resulted in huge reductions in HIV mortality rates. However, disease is not the only scourge in Uganda, and a new study in The Journal of Clinical Pharmacology explores the impact food insecurity may have on treating pregnant women.

18 Feb 2014

Walgreens collaborates with NMAC to improve treatment outcomes for African Americans with HIV

In collaboration with the National Minority AIDS Council, Walgreens is furthering its commitment to improve HIV treatment outcomes for African Americans living with HIV by deepening pharmacists' training and expanding access to the pneumococcal vaccination specifically indicated for persons living with HIV as incidents of flu and pneumonia rise.

11 Feb 2014

Alabama experts develop living document that includes new therapies for Hepatitis C virus

When treatment guidelines for a particular disease emerge, they are often published in a peer-reviewed medical journal, which can take up to three years. One University of Alabama at Birmingham infectious diseases expert recently helped develop new Hepatitis C virus (HCV) guidelines that can be updated and published as new data emerge and new therapies are approved.

5 Feb 2014

Mylan launches trastuzumab biosimilar for treatment of HER2-positive metastatic breast cancer

Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India.

3 Feb 2014

Researchers gain better understanding of HIV infection through electron microscopy

The human intestinal tract, or gut, is best known for its role in digestion. But this collection of organs also plays a prominent role in the immune system. In fact, it is one of the first parts of the body that is attacked in the early stages of an HIV infection. Knowing how the virus infects cells and accumulates in this area is critical to developing new therapies for the over 33 million people worldwide living with HIV. Researchers at the California Institute of Technology are the first to have utilized high-resolution electron microscopy to look at HIV infection within the actual tissue of an infected organism, providing perhaps the most detailed characterization yet of HIV infection in the gut.

30 Jan 2014

CONRAD receives USAID Pioneers Prize for developing tenofovir gel to reduce HIV infection in women

CONRAD, a leading reproductive health-research organization based at Eastern Virginia Medical School (EVMS), today announced that they are a winner of the United States Agency for International Development (USAID) Science and Technology Pioneers Prize for their work in developing tenofovir gel.

29 Jan 2014

Researchers create vaginal cream using silver nanoparticles to control transmition of HIV

The product has proven efficiency in lab tests, although clinical trials are yet to be performed. After discovering that silver nanoparticles are capable of blocking the entry of Human Immunodeficiency Virus (HIV) into the organism, a group of researchers from the University of Texas, in collaboration with Humberto Lara Villegas, specialist in nanoparticles and virology from the University of Monterrey, Mexico (UDEM), create a vaginal cream to control the transmition of the virus.

28 Jan 2014

Mylan Pharmaceuticals launches Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg. This product is the generic version of Novo Nordisk's Prandin, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

24 Jan 2014

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

ViiV Healthcare today announced that the European Commission has approved Tivicay (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.

21 Jan 2014

Study: Pro-inflammatory molecules linked with early death in HIV patients who abuse alcohol

A study led by researchers at Boston University School of Medicine (BUSM) provides new insight into the impact that pro-inflammatory molecules have on early death in HIV patients who abuse alcohol.

17 Jan 2014

Study: HIV-specific poison kills persisting HIV-infected cells during antiretroviral therapy

A team including University of North Carolina and NIH scientists has demonstrated in a mouse model that an HIV-specific poison can kill cells in which the virus is actively reproducing despite antiretroviral therapy.

10 Jan 2014

Researchers deploy potential new weapon against HIV

Researchers at the UNC School of Medicine have deployed a potential new weapon against HIV - a combination therapy that targets HIV-infected cells that standard therapies cannot kill.

10 Jan 2014

Mylan announces launch of Mycophenolic Acid Delayed-release Tablets

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Mycophenolic Acid Delayed-release Tablets, 180 mg and 360 mg. This product is the generic version of Novartis' Myfortic Delayed-release Tablets.

9 Jan 2014

Zyomyx's MyT4 point-of-care CD4 diagnostic test receives CE mark approval

Mylan, Inc. today announced that Zyomyx's MyT4 point-of-care CD4 diagnostic test has received the CE Certificate of Conformity in the European Union, an important step toward launching this innovative test and expanding access to affordable, accessible and reliable diagnostics for people living with HIV globally.

9 Jan 2014

Merck announces FDA approval of ISENTRESS for oral suspension

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration recently approved ISENTRESS for oral suspension, a new pediatric formulation of Merck's integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients four weeks of age and older.

9 Jan 2014

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

Cryptosporidium parvum is one of the most common enteropathogens to affect humans in the world. The protozoan parasite causes a gut infection referred to as cryptosporidiosis.

8 Jan 2014

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today the Company has received approval from the United States Food and Drug Administration (FDA) to commence patient screening of a Phase 2b study of PRO 140, a monoclonal CCR5 antibody, for the treatment of patients with Human Immunodeficiency Virus Type 1.

8 Jan 2014

Mylan launches Tolterodine Tartrate ER Capsules, 2 mg and 4 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.

7 Jan 2014

Population Council gets USAID cooperative agreement to develop non-ARV microbicides that block HIV, STI

The Population Council today announced it was awarded a cooperative agreement from the US Agency for International Development's (USAID) Office of HIV and AIDS: "Non-ARV Based Combination Microbicide that Blocks HIV and Other STIs."

6 Jan 2014

The fight against HIV/AIDS: an interview with Dr. Mit Philips, HIV/AIDS Policy Analyst, Médecins Sans Frontières (MSF)

People mainly speak about the progress in HIV/AIDS. We at MSF know and are very conscious of the fact that there has been enormous progress, but the progress is very uneven.

6 Jan 2014

Antiretroviral News and Research

New study explores the effect of food insecurity on treating HIV-infected pregnant women in Uganda

Walgreens collaborates with NMAC to improve treatment outcomes for African Americans with HIV

Alabama experts develop living document that includes new therapies for Hepatitis C virus

Mylan launches trastuzumab biosimilar for treatment of HER2-positive metastatic breast cancer

Researchers gain better understanding of HIV infection through electron microscopy

CONRAD receives USAID Pioneers Prize for developing tenofovir gel to reduce HIV infection in women

Researchers create vaginal cream using silver nanoparticles to control transmition of HIV

Mylan Pharmaceuticals launches Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

Study: Pro-inflammatory molecules linked with early death in HIV patients who abuse alcohol

Study: HIV-specific poison kills persisting HIV-infected cells during antiretroviral therapy

Researchers deploy potential new weapon against HIV

Mylan announces launch of Mycophenolic Acid Delayed-release Tablets

Zyomyx's MyT4 point-of-care CD4 diagnostic test receives CE mark approval

Merck announces FDA approval of ISENTRESS for oral suspension

C. parvum and cryptosporidiosis: an interview with Dr. Momar Ndao, McGill University

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

Mylan launches Tolterodine Tartrate ER Capsules, 2 mg and 4 mg

Population Council gets USAID cooperative agreement to develop non-ARV microbicides that block HIV, STI

The fight against HIV/AIDS: an interview with Dr. Mit Philips, HIV/AIDS Policy Analyst, Médecins Sans Frontières (MSF)

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News